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PURPOSE. The purpose of this study was to evaluate the impact of supplemental macular
carotenoids (including versus not including meso-zeaxanthin) in combination with
coantioxidants on visual function in patients with nonadvanced age-related macular
degeneration.
METHODS. In this study, 121 participants were randomly assigned to group 1 (Age-Related Eye
Disease Study 2 formulation with a low dose [25 mg] of zinc and an addition of 10 mg meso-
zeaxanthin; n ¼ 60) or group 2 (Age-Related Eye Disease Study 2 formulation with a low dose
[25 mg] of zinc; n ¼ 61). Visual function was assessed using best-corrected visual acuity,
contrast sensitivity (CS), glare disability, retinal straylight, photostress recovery time, reading
performance, and the National Eye Institute Visual Function Questionnaire-25. Macular
pigment was measured using customized heterochromatic flicker photometry.
RESULTS. There was a statistically significant improvement in the primary outcome measure
(letter CS at 6 cycles per degree [6 cpd]) over time (P ¼ 0.013), and this observed
improvement was statistically comparable between interventions (P ¼ 0.881). Statistically
significant improvements in several secondary outcome visual function measures (letter CS at
1.2 and 2.4 cpd; mesopic and photopic CS at all spatial frequencies; mesopic glare disability at
1.5, 3, and 6 cpd; photopic glare disability at 1.5, 3, 6, and 12 cpd; photostress recovery time;
retinal straylight; mean and maximum reading speed) were also observed over time (P < 0.05,
for all), and were statistically comparable between interventions (P > 0.05, for all).
Statistically significant increases in macular pigment at all eccentricities were observed over
time (P < 0.0005, for all), and the degree of augmentation was statistically comparable
between interventions (P > 0.05).
CONCLUSIONS. Antioxidant supplementation in patients with nonadvanced age-related macular
degeneration results in significant increases in macular pigment and improvements in CS and
other measures of visual function. (Clinical trial, http://www.isrctn.com/ISRCTN13894787).
Keywords: randomized clinical trial, lutein, zeaxanthin, meso-zeaxanthin, macular pigment,
age-related macular degeneration, visual function, visual acuity, contrast sensitivity, macular
pigment, NEI VFQ-25, photostress recovery time, reading performance, glare disability, retinal
straylight
AMD is a multifactorial disease characterized by a spectrumof degenerative changes at the macula, ultimately leading to
central vision impairment in many cases. Given the growing
and aging world population, the number of people suffering
from AMD continues to rise. Wong et al.1 estimated the
prevalence of any AMD (globally) to be 8.7% in those aged 45 to
85 years and predicted that the number of people afflicted with
AMD worldwide will be 288 million by 2040. In the Republic of
Ireland, the current prevalence of (any) AMD among persons
aged 50 years and older is estimated to be 7.2%.2 Beyond the
personal suffering of those afflicted with advanced AMD, which
includes loss of central vision and associated adverse clinical
events such as increased risk of falls, depression, loneliness,
suicide, and so on,3 the growing prevalence of AMD represents
a huge socioeconomic burden to society and to health care
providers.4 To address this challenge, preventive, retarding, and
vision-optimizing strategies for nonadvanced AMD need to be
explored, and prior work in diseased and nondiseased eyes
indicates that the enhancement of ocular nutrition is worth
pursuing in this endeavor.5
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Meso-zeaxanthin (MZ), zeaxanthin (Z), and lutein (L)
represent the three constituent carotenoids that make up
macular pigment (MP), a yellow pigment found in the macula.
Their anatomic (central and prereceptorial location), biochem-
ical (antioxidant and anti-inflammatory), and optical (short-
wavelength [blue] light-filtering) properties make these com-
pounds ideal candidates to enhance vision and protect against
AMD and its progression.5 The Age Related Eye Disease Study
(AREDS) 2, published in May 2013, examined the role of
supplementation with two of MP’s constituent macular
carotenoids (L and Z, in combination with coantioxidants) in
patients with intermediate AMD.6 The primary outcome
measure (POM; progression to advanced AMD) in AREDS2
failed to reveal a beneficial effect of supplemental L and Z.7
However, secondary analysis, where data were dichotomized
to those supplemented with L and Z versus those not
supplemented with these macular carotenoids, did demon-
strate a beneficial effect in terms of progression to the
advanced form of the disease, especially in those with a low
dietary intake of these carotenoids.7 It is important to note that
AREDS2 was designed and powered to investigate the impact
of supplementation with macular carotenoids plus coantiox-
idants on AMD morphology and on visual acuity, whereas the
current trial (Central Retinal Enrichment Supplementation
Trial 2 [CREST] AMD - CREST Report 2) was designed and
powered to investigate change in psychophysical (visual)
function, in patients with nonadvanced AMD, following
supplementation with the macular carotenoids plus coantiox-
idants.
In terms of assessing visual function in patients with retinal
disease (including AMD), a number of studies have examined
the impact of supplementation with macular carotenoids.8
Indeed, recent studies have reported favorable outcomes on
visual function (e.g., contrast sensitivity [CS] and glare
disability [GD]) in patients with AMD and other retinal
diseases, following supplementation with the macular carot-
enoids using a formulation of MZ:L:Z in a ratio (mg/d) of
10:10:2.9,10 However, given the exploratory nature of those
studies, a double-blind randomized controlled trial (RCT) with
appropriate methodology was warranted. Originally, the
CREST AMD trial planned a placebo-controlled design, but
following publication of AREDS2, the CREST Data Safety and
Monitoring Committee (DSMC) recommended that the design
be amended to reflect the new standard of care and that,
accordingly, the placebo group should be replaced with an
AREDS2 formula containing a lower dose of zinc (25 mg). In
the amended protocol, we chose a lower zinc dose (25 mg)
because the AREDS2 study found no efficacy-lowering effect of
reducing zinc from 80 mg to 25 mg on either visual acuity or
AMD progression.7
In summary, CREST AMD was designed and conducted to
investigate the impact of macular carotenoid supplementation
with coantioxidants on visual function in patients with non-
advanced AMD during a 2-year period (ISRCTN13894787).11 We
also investigated whether the addition of 10 mg of MZ to a
formulation containing standard AREDS2 doses of L and Z and in
combination with coantioxidants offered advantages/disadvan-




Details of the CREST design and methodology have been
reported elsewhere and are briefly summarized here.11 Ethical
approval was granted by the Research Ethics Committee of the
Waterford Institute of Technology (reference number 12/CLS/
02), Waterford, Ireland, and the Ethics Committee of the
European Research Council (reference number 281096). As
explained previously, following the AREDS2 report, the CREST
protocol was amended from a placebo-controlled design to a
double-blind, head-to-head, RCT (ISRCTN13894787) in which
participants were randomly assigned to two parallel groups,
each receiving active supplements as follows: group 1, 10 mg/d
MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d vitamin C, 400
international units (IU)/d of vitamin E, 25 mg/d zinc, and 2 mg/d
copper (Macushield Gold [Alliance Pharma PLC & Alliance
Pharmaceuticals Ltd, Chippenham Wiltshire, England, UK];
Macuhealth Plus [MacuHealth Limited Partnership, Birmingham,
MI, USA]); and group 2, 10 mg/d L, 2 mg/d Z plus 500 mg/d
vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d
copper (AREDS2 formula with a lower dose of zinc [25 mg]
custom prepared for CREST AMD and not commercially
available). The group 2 intervention, therefore, represents the
standard of care (AREDS2 formula with a lower dose of zinc [25
mg]), whereas group 1 also represents the same standard of
care, but with the addition of 10 mg of MZ. All protocol changes
were approved by the DSMC and the Research Ethics
Committee of the Waterford Institute of Technology, Waterford,
Ireland, and the Ethics Committee of the European Research
Council (Saint-Josse-ten-Noode, Brussels, Belgium). In addition,
protocol changes were published on the International Standard
RCT registration website (www.isrctn.com/ISRCTN13894787)
and in the published methodology11 for this project. Participants
in each group were instructed to take the study intervention
daily with a meal for 2 years. The trial was conducted at the
Macular Pigment Research Group, Nutrition Research Centre
Ireland (Waterford, Ireland) from November 2013 (first visit of
first participant) to May 2016 (last visit of last participant).
Randomization and Intervention
Participants were randomly assigned to intervention groups
using block randomization (block size: 4 and randomization
ratio 1:1). The randomization sequence was generated by the
study statistician (J.S.), and a pharmacist (C.K.) performed
random allocation to intervention groups based on this
randomization sequence at Whitfield Clinic, Waterford, Ireland.
The study investigator (K.O.A.) received, from the pharmacist,
a box of supplements for each study participant, labeled only
with the participant identification number. Only at study
completion, after a masked database review and following
direction from the CREST DSMC, was the randomization
sequence revealed to the study investigator and other data
analysts.
Participants
Inclusion criteria for the trial were as follows: nonadvanced
AMD (1 to 8 on the AREDS 11-step severity scale12 in at least
one eye [the study eye], confirmed by the Moorfields Eye
Hospital Reading Centre, London, UK, an accredited retinal
grading center); best-corrected visual acuity (BCVA) of 6/12
(20/40) or better in the study eye; no more than five diopters
spherical equivalent refraction in the study eye; no previous
consumption of supplements containing the macular caroten-
oids (L and/or Z and/or MZ); no retinal pathology other than
AMD; and no diabetes mellitus (by self-report). The study eye
could be either the right or left eye. If both eyes exhibited
nonadvanced AMD, the eye with the best BCVA was chosen as
the study eye. However, if each eye had the same BCVA and
nonadvanced AMD, the right eye was selected. Each partici-
pant provided written informed consent of their willingness to
participate in the trial, and the examination procedures
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adhered to the tenets of the Declaration of Helsinki. Clinical
assessment was conducted at baseline and at six monthly
intervals during a 2-year period by the study investigator
(K.O.A.) who was trained in all aspects of the CREST protocol.
Retinal photographs were graded in a masked fashion at the
Moorfields Eye Hospital Reading Centre, adhering to the
AREDS 11-step severity scale.12
Outcomes
The POM was change in CS at 6 cycles per degree (cpd)
following 24 months of supplementation (letter CS at 6 cpd).
The Test Chart 2000PRO (Thomson Software Solutions,
Hatfield, UK) was used to assess the POM. Letter CS (instead
of grating CS) at 6 cpd was chosen as our primary outcome
measure because this measure is close to the peak contrast
sensitivity function, and any improvements in CS is best
assessed at this spatial frequency. Furthermore, pilot data were
only available on letter CS (but not grating CS), and this
informed our choice in the current study. Secondary outcome
measures included change in CS at the other spatial
frequencies, BCVA, GD, photostress recovery time (PRT), MP,
retinal straylight, reading acuity, reading speed, subjective
visual function (National Eye Institute Visual Function Ques-
tionnaire–25 [NEI VFQ-25]), and AMD morphology. For
measuring BCVA and letter CS, a Hewlett-Packard monitor
LV916AA2211 (Hewlett-Packard, Palo Alto, CA, USA; resolution
1920 3 1080, luminance 250 cd/m2, dynamic contrast ratio
3,000,000: 1) was used. Prior to use for vision testing, the
device was calibrated in accordance with the instructions
manual from Thomson Software Solutions. Furthermore, all
vision testing was conducted in the same room during the
course of the study.
Compliance and Adverse Event Reporting
Compliance was assessed by contacting participants via
telephone, by capsule counting, and by serum carotenoid
analysis at the end of the study. Participants were also phoned
regularly to ascertain whether they had experienced any
unusual signs/symptoms during the course of the study.
Potential or perceived adverse events were documented and
reported to the DSMC.
Statistical Analysis
A previous report described the sample size/power calculation
for this study.11 Based on an effect size of 0.15 logCS units (one
line on a letter CS chart) for the POM, and a two-tailed test at
the 5% level of significance, we estimated that 56 participants
per intervention group were needed to achieve a power of 80%
for the comparison of the two intervention groups. One eye
(the study eye) of each participant comprised the unit of
analysis. Statistical analysis was performed using IBM SPSS
Statistics for Windows, version 22.0 (Armonk, NY, USA). All
analyses were conducted as per protocol. However, intention-
to-treat (ITT) analysis was also performed, and discrepancies
between ITT analyses and per protocol are reported herein. No
interim analyses were conducted during the course of the
study.
Baseline differences between intervention groups were
assessed using independent samples t-tests for interval
variables and contingency table analyses using the chi-squared
tests for categorical variables.
Most of the outcome variables in this study were changes
(over time) in interval variables (e.g., CS, MP). To compare the
effects of the two intervention groups (on each interval
outcome measure, over time), we used repeated measures
analysis of variance, with time as a within-participants factor
and intervention group as a between-participants factor. In the
ITT analysis, the last observation carried forward was used
when participant data were missing.
Tests of significance, for all comparisons of intervention
groups on interval outcome measures, were two-tailed, and the
5% level of significance was used throughout. We did not
correct for multiple tests, as we were anxious to avoid type II
errors.
RESULTS
Figure 1 shows the Consolidated Standards of Reporting Trials
diagram,13 summarizing the CREST study design, participant
enrolment, randomization, follow-up, and the number of
participants included in study analyses. In this study, 121
participants were enrolled at baseline with 98 participants
completing final assessment at 24 months. Baseline character-
istics (see Table 1) were statistically comparable between
interventions, except for letter CS (1.2 and 2.4 cpd) and
photopic CS at 3 cpd. Losses to follow-up after 2 years of
antioxidant supplementation were statistically comparable
between interventions (P ¼ 0.680, Pearson chi-square).
Primary Outcome Measure
The repeated measures analysis of change in letter CS at 6
cpd (POM) is presented in Table 2 (as per protocol). There
was a statistically significant improvement in the POM
during the study period (P ¼ 0.013 for time effect), but
there was no statistically significant difference between the
intervention groups (P ¼ 0.881 for the time 3 group
interaction effect). Thus, there is no evidence that the two
intervention groups are different with respect to improve-
ment in this measure. Figure 2 graphically illustrates these
findings.
Secondary Outcome Measures
Other Visual Function Outcomes From Baseline to 24
Months. Results from the repeated measures analysis, for
other visual function variables, are also shown in Table 2.
There was a statistically significant improvement (P < 0.05, for
time effect) in most measures of visual function (75%; 24 of 32
of vision-related outcome measures) during the study period,
including CS, PRT, retinal straylight, and GD, and again these
improvements were statistically comparable between interven-
tion groups (P > 0.05). There was one exception; mesopic GD
at 3 cpd (P ¼ 0.040 for the time 3 group interaction effect),
which improved to a borderline significantly greater extent in
group 2. However, in the subsequent ITT analysis, the disparity
between interventions in terms of mesopic GD at 3 cpd was no
longer significant (P ¼ 0.132 for the time 3 group interaction
effect). Figures 2, 3, and 4 graphically illustrate these findings.
Clinically Significant Contrast Sensitivity Findings
The numbers and proportions of patients exhibiting clinically
meaningful changes (one line or more on a letter CS chart) are
presented in Table 3, where it is evident (especially for CS at
1.2 and 2.4 cpd, but also for the POM) that the percentage of
participants showing a clinically meaningful improvement in
CS over time greatly exceeds the percentage showing a
clinically significant deterioration, and that this observation is
true for each intervention group.
Macular Pigment From Baseline to 24 Months. There
was a statistically significant increase in MP for all eccentric-
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ities during the course of the study (P < 0.0005, for all time
effects), but this increase was statistically comparable between
intervention groups (P > 0.05 for time 3 group interaction
effect at all retinal eccentricities; Table 4). Figure 5 graphically
illustrates these findings.
Serum Carotenoids From Baseline to 24 Months. There
was a statistically significant increase in serum concentrations of
L, Z, and MZ during the course of the study (P < 0.0005, for all
time effects; Table 4). The repeated measures analysis of change
in serum L concentrations over time did not show significant
differences between intervention groups (P¼ 0.111 for the time
3 group interaction effect). Observed increases in serum Z
concentrations were significantly greater in group 2 when
compared with group 1 (P ¼ 0.005 for the time 3 group
interaction effect). Significant increases in serum MZ concen-
trations were observed in group 1, but not in group 2 (P <
0.0005 for the time 3 group interaction effect). In terms of
observed increases in total (composite) serum macular caroten-
oid concentrations (i.e., L, Z, and MZ combined), this measure
increased significantly over time, and no significant difference
between intervention groups (P ¼ 0.241 for the time 3 group
interaction effect) was observed. Figure 6 graphically illustrates
these findings.
Grade of AMD From Baseline to 24 Months. Table 5
shows, within each intervention group, the transition between
these grades from baseline to final study visit at 24 months.
FIGURE 1. CREST AMD consolidated standards of reporting trials flow diagram. d, Participants declined to participate either due to personal
reasons, transportation difficulties, or cataract surgery; *, Participants were initially enrolled based on nondetail grading of retinal photographs
obtained at screening visit, confirming eligibility by the Moorfields Eye Hospital Reading Centre. However, detailed grading of baseline retinal
photographs showed some participants had AMD grades > 8 on the AREDS 11-step severity scale and therefore these participants were excluded
based on a decision by the DSMC.
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TABLE 1. Baseline Characteristics by Intervention Group in the CREST AMD Study (Per Protocol)
Variables Group 1, n ¼ 57* Group 2, n ¼ 61† Sig.
Demographic, lifestyle, and health
Age, y 65.09 6 8.59 64.34 6 9.50 0.657
Body mass index, kg/m2 28.27 6 4.30 27.78 6 4.57 0.551
Blood pressure, mm Hg
Systolic 142.07 6 20.98 138.00 6 24.35 0.334
Diastolic 82.65 6 11.21 79.12 6 9.81 0.070
Sex
Male 18 (45.0) 22 (55.0) 0.607
Female 39 (50.0) 39 (50.0)
Education
Primary 7 (43.8) 9 (56.3) 0.766
Secondary 29 (51.8) 27 (48.2)
Tertiary 21 (45.7) 25 (54.3)
Smoking
Never 29 (50.0) 29 (50.0) 0.933
Past 23 (46.9) 26 (53.1)
Current 5 (45.5) 6 (54.5)
AMD family history
Yes 16 (53.3) 14 (46.7) 0.406
No 31 (44.3) 39 (55.7)
Cardiovascular disease
Yes 5 (50.0) 5 (50.0) 0.804
No 50 (47.6) 55 (52.4)
Hypertension
Yes 17 (48.6) 18 (51.4) 0.970
No 40 (48.2) 43 (51.8)
AMD grades
1-3 13 (43.3) 17 (56.7) 0.528
4-8 44 (50.0) 44 (50.0)
Diet score 26.90 6 12.00 26.26 6 12.03 0.776
Serum carotenoids*
Serum L, lmol/l 0.35 6 0.20 0.34 6 0.22 0.710
Serum Z, lmol/l 0.07 6 0.05 0.07 6 0.05 0.639
Serum MZ, lmol/l 0.00 6 0.01 0.01 6 0.02 0.205
Macular pigment
Densitometer*
0.258 0.79 6 0.24 0.72 6 0.26 0.179
0.58 0.65 6 0.22 0.60 6 0.21 0.204
1.08 0.45 6 0.16 0.45 6 0.17 0.927
1.758 0.32 6 0.12 0.31 6 0.15 0.933
Vision
Best corrected visual acuity, VAR
Study eye 100.04 6 5.83 100.08 6 5.62 0.965
Fellow eye 94.63 6 10.95 95.92 6 12.20 0.549
Letter contrast sensitivity, LogCS
1.2 cpd 1.77 6 0.17 1.85 6 0.16 0.007
2.4 cpd 1.76 6 0.21 1.83 6 0.18 0.045
6 cpd, POM 1.49 6 0.25 1.56 6 0.21 0.108
9.6 cpd 1.23 6 0.30 1.32 6 0.25 0.082
15.15 cpd* 0.86 6 0.35 0.94 6 0.29 0.160
Mesopic contrast sensitivity, LogCS
1.5 cpd 1.53 6 0.22 1.61 6 0.21 0.065
3 cpd 1.62 6 0.23 1.68 6 0.18 0.106
6 cpd 1.21 6 0.35 1.33 6 0.35 0.065
12 cpd 0.78 6 0.27 0.85 6 0.28 0.132
18 cpd 0.33 6 0.12 0.32 6 0.11 0.749
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Importantly, no participant from Group 1 (the intervention
containing MZ) and only one participant from Group 2
progressed to advanced AMD over the study period.
Compliance
The compliance to study intervention (as measured by capsule
counting) was not significantly different between intervention
groups during the course of the study (P¼0.342 for the time3
group interaction effect). In addition, serum carotenoid
assessment indicated good compliance to study intervention
(see Fig. 6).
Adverse Events
The distribution of potential or perceived adverse events
reported during the course of the study is shown in Table 6.
Some participants reported more than one adverse event. The
proportion of participants experiencing any adverse event was
statistically similar between interventions: 15 (26%) of 57 from
group 1 and 10 (16%) of 61 from group 2 (P¼ 0.187, Pearson
chi-squared test). No serious adverse event relating to the study
intervention was reported in either intervention group during
the course of the study.
DISCUSSION
This RCT was designed to compare the impact of two different
macular carotenoid formulations, in combination with coan-
tioxidants, on visual function in patients with nonadvanced
AMD. The AMD disease status of participants was graded using
the AREDS 11-step severity scale12 and included only eyes
TABLE 1. Continued
Variables Group 1, n ¼ 57* Group 2, n ¼ 61† Sig.
Photopic contrast sensitivity, LogCS
1.5 cpd 1.46 6 0.19 1.52 6 0.16 0.061
3 cpd 1.72 6 0.22 1.80 6 0.19 0.047
6 cpd 1.58 6 0.31 1.68 6 0.31 0.079
12 cpd 1.19 6 0.38 1.27 6 0.35 0.279
18 cpd 0.51 6 0.34 0.62 6 0.34 0.081
Mesopic glare disability, LogCS
1.5 cpd 0.91 6 0.32 0.99 6 0.29 0.193
3 cpd 1.11 6 0.37 1.19 6 0.32 0.241
6 cpd 0.93 6 0.25 0.93 6 0.23 0.977
12 cpd 0.66 6 0.15 0.63 6 0.11 0.355
18 cpd 0.30 6 0.00 0.31 6 0.04 0.336
Photopic glare disability, LogCS
1.5 cpd 1.40 6 0.21 1.46 6 0.17 0.082
3 cpd 1.67 6 0.22 1.73 6 0.18 0.130
6 cpd 1.51 6 0.32 1.58 6 0.31 0.210
12 cpd 1.11 6 0.36 1.19 6 0.36 0.206
18 cpd 0.52 6 0.35 0.56 6 0.31 0.583
Retinal Straylight 1.30 6 0.18 1.33 6 0.25 0.381
Photostress recovery time, s 15.98 6 8.72 15.97 6 7.99 0.996
Reading performance
Reading acuity, LogRAD 0.12 6 0.13 0.09 6 0.12 0.165
Mean reading speed, w/min 154.48 6 26.82 156.45 6 27.53 0.694
Maximum reading speed, w/min 199.61 6 31.58 201.56 6 34.44 0.749
National Eye Institute Questionnaire-25
Overall vision score 87.80 6 9.96 90.38 6 9.22 0.147
Data displayed are mean 6 standard deviation for interval data and percentages, n (%), for categorical data; the percentages displayed are row
percentages. Sig., significance set at P < 0.05. Education, highest level of education; Smoking, Never (<100 cigarettes in lifetime), Past (smoked ‡100
cigarettes in lifetime and none in past year), current (smoked ‡100 cigarettes in lifetime and at least one in the last year). *, n „ 57 in group 1 and/or n „
61 in group 2 as certain tests/measures were not obtained. VAR, visual acuity rating. VAR¼ 100 50 LogMAR, a score of 100 corresponds with 20/20 (6/
6); LogCS, logarithm of contrast sensitivity units. Family history of AMD means having a first degree relative, that is, parent or sibling, with AMD AREDS 11-
step scale. Diet score, estimated dietary intake of lutein and zeaxanthin using the ‘‘L/Z screener’’ developed by Professor Elizabeth Johnson, Tufts
University. Macular pigment measured using the Macular Densitometer (Macular Metrics Corp.). Serum macular carotenoids analyzed by HPLC. Best-
corrected visual acuity measured with the Test Chart 2000 Xpert (Thomson Software Solutions). Letter contrast sensitivity measured using the Test Chart
2000 PRO (Thomson Software Solutions). Mesopic and photopic contrast sensitivity measured using the Functional Vision Analyzer (Stereo Optical Co.).
Mesopic and photopic glare disability measured using the Functional Vision Analyzer (Stereo Optical Co.). Retinal straylight measured using the Oculus C-
Quant (Oculus GmbH, Wetzler, Germany) and recorded in logarithms (judged reliable when estimated standard deviation (ESD)  0.08 and Q ‡ 1).
Photostress recovery time measured by assessing the time of recovery after a 10-second exposure to a 300-watt tungsten spotlight (ARRI 300 Plus lamp,
ARRI Lighting Solutions GmbH, Berlin, Germany) with a low-pass glass dichroic filter. Reading performance assessed using the English version of the
standardized Radner reading chart at a distance of 40 cm with reading correction. Reading acuity recorded in logarithm of the reading acuity
determination (LogRAD). The following formula was used to calculate the LogRAD-score: logRADþ total number of incorrectly read syllables3 0.005.
Reading speed (the time taken to read the number of words in a sentence) was measured in words per minute (w/min) with a stop watch for each
standardized sentence (14 words360 seconds divided by reading time in seconds). National Eye Institute Visual Function Questionnaire–25 overall vision
scores range from zero (worst) to 100 (best).
* Group 1, 10 mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper.
† Group 2, 10 mg/d L, 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper.
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Group 2† Time Time 3 Group
Baseline 24 Months Baseline 24 Months Effect Interaction
Mean SD Mean SD Mean SD Mean SD Sig. Sig.
Vision
Best corrected visual acuity, VAR 46 101.22 5.16 100.91 5.80 51 100.78 5.08 101.31 5.20 0.746 0.233
Letter contrast sensitivity, LogCS
1.2 cpd 46 1.79 0.17 1.89 0.20 51 1.86 0.14 1.91 0.16 <0.0005 0.058
2.4 cpd 46 1.78 0.22 1.86 0.22 51 1.85 0.16 1.91 0.18 <0.0005 0.582
6 cpd, POM 46 1.53 0.24 1.57 0.29 51 1.58 0.18 1.61 0.23 0.013 0.881
9.6 cpd 46 1.29 0.28 1.31 0.30 51 1.36 0.21 1.38 0.26 0.154 0.925
15.15 cpd 46 0.92 0.33 0.95 0.34 51 0.96 0.27 1.01 0.33 0.082 0.747
Mesopic contrast sensitivity, LogCS
1.5 cpd 46 1.55 0.22 1.62 0.24 51 1.63 0.21 1.70 0.23 0.007 0.982
3 cpd 46 1.63 0.24 1.76 0.27 51 1.69 0.18 1.84 0.27 <0.0005 0.523
6 cpd 46 1.25 0.35 1.48 0.45 51 1.34 0.34 1.49 0.42 <0.0005 0.228
12 cpd 46 0.81 0.29 0.94 0.36 51 0.87 0.28 0.96 0.35 0.002 0.605
18 cpd 46 0.33 0.13 0.39 0.23 51 0.31 0.08 0.41 0.25 <0.0005 0.369
Photopic contrast sensitivity, LogCS
1.5 cpd 46 1.47 0.19 1.60 0.23 51 1.53 0.16 1.64 0.21 <0.0005 0.862
3 cpd 46 1.75 0.23 1.84 0.23 51 1.82 0.18 1.91 0.21 <0.0005 0.986
6 cpd 46 1.63 0.28 1.74 0.39 51 1.70 0.29 1.81 0.34 <0.0005 0.934
12 cpd 46 1.25 0.37 1.34 0.43 51 1.30 0.33 1.34 0.37 0.015 0.468
18 cpd 46 0.56 0.36 0.71 0.44 51 0.65 0.34 0.69 0.36 0.008 0.174
Mesopic glare disability, LogCS
1.5 cpd 46 0.98 0.32 1.08 0.44 51 1.01 0.29 1.20 0.45 <0.0005 0.172
3 cpd 46 1.19 0.36 1.22 0.43 51 1.22 0.30 1.38 0.41 0.001 0.040
6 cpd 46 0.97 0.27 1.05 0.35 51 0.94 0.23 1.09 0.35 <0.0005 0.222
12 cpd 46 0.67 0.16 0.68 0.22 51 0.64 0.12 0.69 0.18 0.133 0.412
18 cpd 46 0.30 0.00 0.32 0.10 51 0.31 0.04 0.31 0.08 0.197 0.486
Photopic glare disability, LogCS
1.5 cpd 46 1.43 0.21 1.55 0.26 51 1.47 0.18 1.55 0.24 <0.0005 0.364
3 cpd 46 1.70 0.22 1.82 0.25 51 1.74 0.18 1.83 0.24 <0.0005 0.542
6 cpd 46 1.56 0.31 1.65 0.40 51 1.61 0.29 1.70 0.34 0.001 0.987
12 cpd 46 1.18 0.34 1.26 0.41 51 1.23 0.33 1.31 0.38 0.011 0.913
18 cpd 46 0.58 0.37 0.60 0.39 51 0.57 0.31 0.62 0.33 0.179 0.646
Retinal Straylight, Logs 41 1.29 0.18 1.25 0.19 43 1.33 0.20 1.26 0.16 0.004 0.359
Photostress recovery time, s 46 16.93 9.19 12.47 6.79 51 16.00 8.51 10.96 6.05 <0.0005 0.757
Reading performance
Reading acuity, LogRAD 46 0.09 0.12 0.09 0.08 51 0.07 0.10 0.06 0.10 0.637 0.759
Mean reading speed, w/min 46 154.61 27.11 189.89 26.53 51 158.75 27.00 192.82 28.54 <0.0005 0.765
Maximum reading speed, w/min 46 200.44 32.25 244.00 35.02 51 204.74 33.40 245.38 37.90 <0.0005 0.606
National Eye Institute Questionnaire-25
Overall vision score 46 89.24 7.95 89.27 9.61 50 90.83 9.66 91.93 7.01 0.408 0.434
N, participants with data at all study visits; Sig., significance set at P < 0.05. P values obtained from repeated measures analysis of variance. Best-
corrected visual acuity measured with the Test Chart 2000 Xpert (Thomson Software Solutions). Letter contrast sensitivity measured using the Test
Chart 2000 PRO (Thomson Software Solutions). Mesopic and photopic contrast sensitivity measured using the Functional Vision Analyzer (Stereo
Optical Co.). Mesopic and photopic glare disability measured using the Functional Vision Analyzer (Stereo Optical Co.). Retinal straylight measured
using Oculus C-Quant (Oculus GmbH) and recorded in logarithms (judged reliable when ESD  0.08 and Q ‡ 1). Photostress recovery time
measured by assessing the time of recovery after a 10-second exposure to a 300-watt tungsten spotlight (ARRI 300 Plus lamp) with a low-pass glass
dichroic filter. Reading performance assessed using the English version of the standardized Radner reading chart at a distance of 40 cm with reading
correction. Reading acuity recorded in logarithm of the reading acuity determination (LogRAD). The following formula was used to calculate the
LogRAD score: logRAD þ total number of incorrectly read syllables 3 0.005. Reading speed (the time taken to read the number of words in a
sentence) was measured in words per minute (w/min) with a stop watch for each standardized sentence (14 words360 seconds divided by reading
time in seconds). National Eye Institute Visual Function Questionnaire–25 overall vision scores range from zero (worst) to 100 (best).
* Group 1, 10 mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper.
† Group 2, 10 mg/d L, 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper.
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classed as grade 1 to 8 at baseline (referred to as nonadvanced
AMD for the purpose of the current study). We did not include
eyes with noncentral geographic atrophy (AMD grade 9 on the
AREDS 11-step severity scale). Given the biologically plausible
rationale that benefits, in terms of vision and in terms of MP
augmentation, are more likely to extend to participants with
earlier disease (before irreversible damage has occurred, such
as in noncentral geographic atrophy [grade 9 AREDS 11-step
severity scale]), we purposely recruited eyes at an earlier stage
of disease. We report improvements in a range of measures of
visual function (i.e., CS, GD, PRT, reading speed) following
supplementation with the macular carotenoids in combination
FIGURE 2. Letter contrast sensitivity function using the Test Chart 2000 PRO (Thomson Software Solutions) in the CREST AMD study. Group 1, 10
mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper; group 2, 10 mg/d L, 2 mg/d Z
plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper. Error bars represent standard error of mean.
FIGURE 3. Mesopic and photopic contrast sensitivity function using the Functional Vision Analyzer (Stereo Optical Co., Chicago, IL, USA) in the
CREST AMD study. Group 1, 10 mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d
copper; group 2, 10 mg/d L, 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper. Error bars represent
standard error of mean.
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with coantioxidants, and our results are consistent with
previous studies.9,14,15
A possible explanation for the role that MP plays in
optimizing CS rests on the visibility hypothesis of MP, which
posits that this prereceptorial pigment enhances visualiza-
tion of a target’s detail by the absorption of blue haze.16 Blue
haze is a subjective experience and is caused by scattered
short-wavelength dominant air light (blue light), which
results in a veiling luminance when we view objects at a
distance.16 MP accentuates the luminance of an object
relative to its background by attenuating the impact of this
scattered (veiling) short-wavelength visible blue light on the
FIGURE 4. Mesopic and photopic glare disability using the Functional Vision Analyzer (Stereo Optical Co.) in the CREST AMD study. Group 1, 10
mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper; group 2, 10 mg/d L, 2 mg/d Z
plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper. Error bars represent standard error of mean.
FIGURE 5. Macular pigment response in the CREST AMD study. Group 1, 10 mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d
of vitamin E, 25 mg/d zinc, and 2 mg/d copper; group 2, 10 mg/d L, 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2
mg/d copper. Macular pigment measured using a Macular Densitometer (Macular Metrics Corp., Providence, RI, USA). Error bars represent
standard error of mean.
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just noticeable differences of luminance required for
discernibility and, by consequence, extends the visual
range.17 Indeed, the visibility hypothesis has been tested
empirically and is supported by two studies that have
demonstrated the beneficial effect of MP in this respect
under simulated blue haze conditions.18,19 Beyond this
optical effect, the macular carotenoids may also favorably
influence lateral inhibitory mechanisms20 and may thereby
have contributed to the observed improvements in CS
following supplementation.
Importantly, we believe that the observed improvements in
CS in this trial are clinically meaningful. Recently, Maynard et
al.21 demonstrated that, when compared with age-similar
healthy eyes, patients with nonadvanced AMD exhibit signif-
icantly worse CS (reflecting a deterioration of 0.007 log CS/
year), consistent with the findings of a major review by Neelam
et al.22 In terms of visual performance, visual acuity is a
measure of the ability to correctly identify targets (of variable
size) at 100% contrast, whereas CS is a measure of the ability to
detect/identify targets (of variable sizes [spatial frequencies]) at
varying contrast (i.e., faintness). Furthermore, CS (but not
BCVA) can effectively predict how well patients see targets
typical of everyday life, which has important implications for
quality of life.23 Consequently, good visual acuity in the
presence of poor CS (e.g., nonadvanced cataract) results in
reports of visual complaints,24 particularly for real-world tasks
and targets,23 but the following question remains: what degree
of change in CS will have a clinically meaningful impact for the
patient?
For VA, a one-line change (0.1 log MAR) is considered
clinically meaningful.25 For CS, the available data indicate that a
0.1 log change in the percentage threshold contrast required
for the detection of a target/pattern is equally (if not more)
devastating to visual performance than a deterioration of one
line of BCVA.23,26 In brief, threshold contrast is the contrast
required to see the target reliably; the reciprocal of threshold is
called sensitivity, which is expressed as a percentage (e.g., see
Michelson contrast).27 For example, for spatial frequencies that
are near the peak of the contrast sensitivity function (i.e., 4–6
cycles/degree), younger and middle-aged patients have con-
trast thresholds of, on average, circa 2.5%. A 0.1 log unit
deterioration from this value yields a contrast threshold of
3.2%, which is classed as visual impairment.28 Moreover,
contrast thresholds > 5% are associated with increased risk of
driving accidents.28 Accordingly, a decrease/increase in CS of
0.1 log unit is deemed clinically meaningful; in this study,
19.6% to 34.8% of participants exhibited at least this magnitude
of improvement at three spatial frequencies, whereas this








Group 1* Group 2† Group 1* Group 2†
Letter CS 1.2 cpd 34.8 19.6 2.2 3.9
Letter CS 2.4 cpd 26.1 21.6 4.3 3.9
Letter CS 6 cpd 26.1 21.6 13 11.8
Clinical significance, which for present purposes we defined as one
line or more on a letter CS chart. Letter CS measured using the Test
Chart 2000 PRO (Thomson Software Solutions).
* Group 1, 10 mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d
vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper.
† Group 2, 10 mg/d L, 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d
of vitamin E, 25 mg/d zinc, and 2 mg/d copper.





Group 2† Time Time 3 Group
Baseline 24 Months Baseline 24 Months Effect Interaction
Mean SD Mean SD Mean SD Mean SD Sig. Sig.
Macular pigment
0.258 45 0.80 0.23 1.02 0.15 50 0.72 0.25 1.00 0.16 <0.0005 0.247
0.58 45 0.67 0.23 0.90 0.14 50 0.60 0.22 0.88 0.15 <0.0005 0.334
1.08 45 0.44 0.17 0.66 0.11 50 0.45 0.18 0.63 0.09 <0.0005 0.444
1.758 45 0.32 0.12 0.44 0.10 50 0.31 0.16 0.43 0.13 <0.0005 0.924
Serum carotenoids
Serum L, lmol/l 41 0.34 0.16 1.40 0.83 47 0.33 0.21 1.72 1.06 <0.0005 0.111
Serum Z, lmol/l 40 0.07 0.04 0.14 0.07 46 0.07 0.05 0.19 0.11 <0.0005 0.005
Serum MZ, lmol/l 40 0.00 0.01 0.10 0.08 46 0.00 0.01 0.00 0.01 <0.0005 <0.0005
Serum TC, lmol/l 40 0.41 0.20 1.65 0.96 46 0.40 0.26 1.91 1.18 <0.0005 0.241
Macular pigment measured using the Macular Densitometer (Macular Metrics Corp.). Serum macular carotenoids analyzed by HPLC. Total
carotenoids represent the total (composite) serum macular carotenoid concentrations (i.e., L, Z, and MZ combined). N, participants with data at all
study visits. Sig., Significance set at P < 0.05.
* Group 1, 10 mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper.
† Group 2, 10 mg/d L, 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper.









Baseline Group 1* 13 44 0 57
Group 2† 17 44 0 61
24 months Group 1* 11 35 0 46
Group 2† 11 38 1 50
Low risk, AMD grades 1 to 3 on the AREDS 11-step scale; high risk,
AMD grades 4 to 8 on the AREDS 11-step scale; advanced AMD, AMD
grades 9 to 11 on the AREDS 11-step scale.
* Group 1, 10 mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d
vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper.
† Group 2, 10 mg/d L, 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d
of vitamin E, 25 mg/d zinc, and 2 mg/d copper.
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magnitude of deterioration was demonstrable in only 2.2% to
13% of participants at the same three spatial frequencies.
GD, defined as reduction in visual function caused by a
glare source, results in retinal contrast loss secondary to retinal
straylight.29,30 Clinically, GD can be measured by assessing the
impact of a glare source on visual function (BCVA or CS) or by
the measurement of retinal straylight.30 Of note, the Commis-
sion Internationale de l’Eclairage defines GD in terms of retinal
straylight.29 For the purposes of this study, GD was measured
using each of these aforementioned methods (i.e., by assessing
CS under conditions of glare [in both mesopic and photopic
conditions] using the Functional Vision Analyzer and by
measuring retinal straylight using the Oculus C-Quant).
Mechanisms put forward to explain the observed improve-
ments in CS following MP augmentation in patients with
nonadvanced AMD apply also to the observed improvements
in GD in this population, but with the possibility of an
additional element, which relates the glare hypothesis of MP.31
The glare hypothesis of MP posits that MP augmentation
should improve GD and PRT via its optical (blue light) filtration
properties.31 Of note, the absorption spectrum of MP32
accounts for one third of the visible spectrum, and wave-
lengths of light responsible for GD are those in MP’s absorption
range.31 Therefore, and given that MP filters short-wavelength
light at a prereceptorial level, thereby reducing the adverse
impact of retinal straylight (caused by the glare source) that
casts a veiling luminance on the retina, the observed
improvements in CS under conditions of glare (GD) are
unsurprising.31 Also, improvements in PRT following supple-
mentation may also be explained, at least in part, by the glare
hypothesis of MP.31 In brief, MP attenuates short-wavelength
light from the glare source before it reaches the photorecep-
tors, thereby reducing its impact on photopigment bleaching,
and, consequently, reducing the recovery time (i.e., the time it
takes for vision to be restored).
The observed improvement in reading speed as a conse-
quence of supplementation may be attributed to visual and/or
nonvisual (neurocognitive) factors. In terms of the visual
factors, reading speed is a function of both spatial and
temporal CS,33 and we have already discussed the mechanisms
whereby antioxidant supplementation resulted in an improve-
ment in two aspects of spatial vision (CS and GD). In terms of
temporal vision, it has been shown that MP is positively related
to critical flicker fusion frequency and to the full temporal CS
function measured at the fovea but not the parafovea.34
Furthermore, supplemental macular carotenoids have been
shown to increase critical flicker fusion frequency thresholds
and visual motor reaction time in young healthy participants.35
Thus, MP could improve reading speed by its effects on
temporal vision (i.e., increasing temporal processing speeds).
Indeed, Stringham and Stringham36 have suggested that
temporal visual mechanisms compensate for MP’s optical
FIGURE 6. Serum carotenoid response in the CREST AMD study. Group 1, 10 mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d
of vitamin E, 25 mg/d zinc, and 2 mg/d copper; group 2, 10 mg/d L, 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2
mg/d copper. Serum macular carotenoids analyzed by HPLC. Serum total macular carotenoids represent the addition of serum lutein, zeaxanthin,
and meso-zeaxanthin concentrations obtained at each study visit. Error bars represent standard error of mean.
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filtration properties by reducing temporal input from the short-
wavelength cone system and increasing temporal processing
by the middle/long wavelength cone system. These aspects of
temporal vision may be enhanced following supplementation
with the macular carotenoids35 and may lead to subsequent
improvements in reading speed.
Vision-related quality of life questionnaires are known to
correlate with subjective measures of visual function (e.g., CS
and reading speed),37 and, therefore, it is likely that
improvements in these parameters will result in improved
quality of life. Scilley et al.38 reported that persons with
nonadvanced AMD have good visual acuity, but are likely to
have problems with night driving, near vision tasks, and GD
when compared with persons with no retinal disease (age-
matched controls with normal retinal health). Visual acuity, CS,
and reading speed are known determinants of vision-related
quality of life in patients with nonadvanced AMD,39 reflected
in the findings of the Los Angeles Latino Eye Study, where
nonadvanced AMD lesions (i.e., soft indistinct drusen and
pigmentary abnormalities) were associated with a lower self-
reported vision-related quality of life.40 Therefore, the ob-
served improvements in visual function parameters (in the
current study) are likely to impact favourably on quality of life
of patients with nonadvanced AMD. However, our vision-
related quality of life instrument (NEI VFQ-25) did not show
any statistically significant improvements following supple-
mentation with macular carotenoids (in combination with
coantioxidants), and we suspect that a larger number of
participants will be required to do so with such an instrument.
For instance, to detect a two-point difference between
interventions in the NEI VFQ-25 overall score (assuming a 5%
level of significance, 80% power ,and two-tailed test), the
required sample size would be 3136 participants (1568 per
intervention group).41
Eye care professionals should be aware of the observed
visual benefits afforded to patients with nonadvanced AMD as a
result of supplementation with macular carotenoids (and
coantioxidants) in the short, medium, and long terms, and
the indication for recommending such supplements should no
longer be limited to risk reduction for disease progression in
the long term. Also, and importantly, further augmentation of
MP and further improvements in psychophysical function are
realized in patients with nonadvanced AMD after 24 months of
sustained supplementation, and it may well be that the
improvements observed in this study (duration of 24 months)
understate the visual improvements that patients can expect.9
Given that psychophysical function is compromised in
nonadvanced AMD in a way that is commensurate with the
stage of nonadvanced AMD and given that AMD is a progressive
disease, our findings of visual improvements in a condition
where visual deterioration is expected is as interesting as it is
welcome. If psychophysical visual function can be improved in
a progressive condition (such as nonadvanced AMD), it is
tempting to hypothesize that improvements in psychophysical
function herald regression of the morphological changes that
underpin them. However, longer term studies with larger
numbers of patients with nonadvanced AMD, and with regular
monitoring of MP and psychophysical function as well as
morphological changes, are required to confirm or refute this
hypothesis.
It is possible that some of our reported improvements in
psychophysical measures of visual function (e.g., reading
speed) may be due to learning effects, but given that we had
no placebo group (which represents a limitation of our study)
it is difficult to ascertain to what level (if any). It is also
important to point out that reading speed was not a primary
outcome measure in this trial. However, given the long periods
of time between study visits, we feel that these learning effects
are likely to be minimal. It should also be appreciated that
these improvements in for example, reading speed, were
observed in patients suffering from a condition associated with
progressive visual deterioration and at a time of life when
speed of neural processing declines.
Of note, the MP levels reported at baseline may be
considered high.42 This suggests that the current study was
representative of a very well-nourished population and this
may have, in fact, resulted in understating the benefits of
supplementation that may have been seen in a less well-
nourished population (as was the case in subgroup analyses of
the AREDS2 cohort).43
In this study, we measured MP using two devices; namely
the Densitometer (Macular Metrics) and the Spectralis HRA-
OCT MultiColor (Heidelberg Engineering, GmbH, Heidelberg,
Germany). In a previous report, using data from the current
study, we found that measures of MP using these two devices
are not impressively concordant, although each of these two
devices is capable of detecting statistically significant changes
in MP over time, within a given eye, following supplementa-
tion with MP’s constituent carotenoids.44 Furthermore, anoth-
er recent study has found that MP measurement using the







Any adverse event 15 10
Ocular
Watery eyes 1 1
Transient blurred vision 1 0
Gritty eyes 1 0
Ocular pain 1





Itchy skin 1 1
Metallic taste in mouth 1 1
Heat rash 0 2
Irritable bowel syndrome 1 0
Night-time urination 1 0
Headaches 1 0
Weight gain 1 0
Overactive kidney 0 1
Leg cramps 1 0
Knee ache 1 0
Red and swollen arms and legs 0 1
Dizziness 1 0
Neck stiffness 1 0
Abdominal pains 0 1
Pancreatitis 0 1
Palpitations 1 0
Sleep disturbance 1 0
Swollen face 0 1
Hallucinations 0 1
Swollen ankle 0 1
Loss of appetite 0 1
Data expressed as number of participants. Some participants
reported more than one adverse event.
* Group 1, 10 mg/d MZ, 10 mg/d L, and 2 mg/d Z plus 500 mg/d
vitamin C, 400 IU/d of vitamin E, 25 mg/d zinc, and 2 mg/d copper.
† Group 2, 10 mg/d L, 2 mg/d Z plus 500 mg/d vitamin C, 400 IU/d
of vitamin E, 25 mg/d zinc, and 2 mg/d copper.
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Spectralis is affected by cataract.45 Thus, in the current study,
which included patients with varying severity of lens
opacification, we elected (following advice from the DSMC)
to use the MP measures from the Densitometer, which are
robust to cataract.46,47
The strengths of this study include its randomized,
controlled, and double-masked design, the range of parame-
ters of visual function assessed, the fact that MP was
measured and monitored using an established and validated
technique, and the determination of serological responses
and that AMD was graded in a masked fashion by an
accredited reading center. Finally, the study was overseen
by an independent DSMC.
A study limitation (albeit slight) is the failure to reach the
intended sample size of 56 participants per group; actual
samples sizes were 51 and 46. However, because we elected to
use repeated measures analysis of variance, rather than the
independent-samples t-tests on which the original sample size
calculations had been based, our statistical tests (of time and
time 3 supplement interaction effects) were based on the t-
distribution with more than 90 degrees of freedom, that is,
these tests were more than adequately powered.
Another study limitation is the absence of a placebo arm.
However, as already noted, the original study protocol had a true
placebo, but that protocol had to be revised on ethical grounds,
following publication of the AREDS2 findings. We did not
measure the serum concentrations of any of the co-antioxidants
(vitamin C, E, zinc, and copper) in this RCT. We do, however,
report serum response of the macular carotenoids, which was
important in the assessment of compliance, and that allowed us
to investigate whether participants were responding to the
nutrients of interest. Assessing the concentrations of the
coantioxidants may have yielded insights into the interrelation-
ships/interactions between these compounds and the macular
carotenoids, and future studies may consider adopting such an
approach. Correction for multiple testing was not performed in
the current study. It is therefore possible that some of our
reported significant results may be attributable to type 1 errors.
However, many of the reported P values in this study would still
be significant after Bonferroni adjustment.
In summary, supplementation with a formulation that
contains the macular carotenoids (with or without MZ), in
combination with coantioxidants, results in improvements in
contrast sensitivity and other measures of visual function in
patients with nonadvanced AMD.
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